Bafna Pharmaceuticals Limited (BAFNAPH) - Total Assets

Latest as of March 2026: Rs1.76 Billion INR ≈ $18.98 Million USD

Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) holds total assets worth Rs1.76 Billion INR (≈ $18.98 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BAFNAPH operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Bafna Pharmaceuticals Limited - Total Assets Trend (2005–2026)

This chart illustrates how Bafna Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. See Bafna Pharmaceuticals Limited net assets for net asset value and shareholders' equity analysis.

Bafna Pharmaceuticals Limited - Asset Composition Analysis

Current Asset Composition (March 2026)

Bafna Pharmaceuticals Limited's total assets of Rs1.76 Billion consist of 51.1% current assets and 48.9% non-current assets.

Asset Category	Amount (INR)	% of Total Assets
Cash & Equivalents	Rs0.00	1.2%
Accounts Receivable	Rs440.07 Million	25.1%
Inventory	Rs289.03 Million	16.5%
Property, Plant & Equipment	Rs0.00	0.0%
Intangible Assets	Rs0.00	0.0%
Goodwill	Rs0.00	0.0%

Asset Composition Trend (2005–2026)

This chart illustrates how Bafna Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Bafna Pharmaceuticals Limited.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Bafna Pharmaceuticals Limited's current assets represent 51.1% of total assets in 2026, a decrease from 78.4% in 2005.
Cash Position: Cash and equivalents constituted 1.2% of total assets in 2026, down from 6.9% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
Asset Diversification: The largest asset category is accounts receivable at 25.1% of total assets.

Bafna Pharmaceuticals Limited Competitors by Total Assets

Key competitors of Bafna Pharmaceuticals Limited based on total assets are shown below.

Company	Country	Total Assets
Takeda Pharmaceutical Company Limited F:TKDA	Germany	€15.41 Trillion
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	China	CN¥19.57 Billion
Beijing Sun Novo Pharmaceutical Research Co Ltd SHG:688621	China	CN¥2.30 Billion
Guizhou Xinbang Pharmaceutical Co Ltd SHE:002390	China	CN¥8.59 Billion
Guangdong Lifestrong Pharmacy Co. Ltd. SHE:301111	China	CN¥925.41 Million
Jw Pharmac KO:001060	Korea	₩605.27 Billion
Kamada TA:KMDA	Israel	ILA377.21 Million
Samjin Pharm KO:005500	Korea	₩449.14 Billion

Bafna Pharmaceuticals Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.57	1.63	2.04
Quick Ratio	1.06	1.09	1.41
Cash Ratio	0.00	0.00	0.00
Working Capital	Rs324.62 Million	Rs328.76 Million	Rs253.59 Million

Bafna Pharmaceuticals Limited - Advanced Valuation Insights

This section examines the relationship between Bafna Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.94
Latest Market Cap to Assets Ratio	0.04
Asset Growth Rate (YoY)	14.7%
Total Assets	Rs1.76 Billion
Market Capitalization	$68.61 Million USD

Valuation Analysis

Below Book Valuation: The market values Bafna Pharmaceuticals Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Bafna Pharmaceuticals Limited's assets grew by 14.7% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Bafna Pharmaceuticals Limited (2005–2026)

The table below shows the annual total assets of Bafna Pharmaceuticals Limited from 2005 to 2026.

Year	Total Assets	Change
2026-03-31	Rs1.76 Billion ≈ $18.98 Million	+14.67%
2025-03-31	Rs1.53 Billion ≈ $16.55 Million	+3.65%
2024-03-31	Rs1.48 Billion ≈ $15.97 Million	+13.97%
2023-03-31	Rs1.30 Billion ≈ $14.01 Million	+43.75%
2022-03-31	Rs901.45 Million ≈ $9.75 Million	+4.25%
2021-03-31	Rs864.66 Million ≈ $9.35 Million	+21.25%
2020-03-31	Rs713.13 Million ≈ $7.71 Million	-40.31%
2019-03-31	Rs1.19 Billion ≈ $12.92 Million	-13.65%
2018-03-31	Rs1.38 Billion ≈ $14.96 Million	-22.40%
2017-03-31	Rs1.78 Billion ≈ $19.28 Million	-7.38%
2016-03-31	Rs1.93 Billion ≈ $20.82 Million	-3.66%
2015-03-31	Rs2.00 Billion ≈ $21.61 Million	-15.26%
2014-03-31	Rs2.36 Billion ≈ $25.50 Million	-9.50%
2013-03-31	Rs2.61 Billion ≈ $28.18 Million	+19.02%
2012-03-31	Rs2.19 Billion ≈ $23.68 Million	+61.43%
2011-03-31	Rs1.36 Billion ≈ $14.67 Million	+61.21%
2010-03-31	Rs841.28 Million ≈ $9.10 Million	+8.09%
2009-03-31	Rs778.29 Million ≈ $8.42 Million	+52.23%
2008-03-31	Rs511.27 Million ≈ $5.53 Million	-5.34%
2007-03-31	Rs540.09 Million ≈ $5.84 Million	+151.65%
2006-03-31	Rs214.62 Million ≈ $2.32 Million	+27.36%
2005-03-31	Rs168.51 Million ≈ $1.82 Million	--

About Bafna Pharmaceuticals Limited

NSE:BAFNAPH India Drug Manufacturers - Specialty & Generic

Market Cap

$68.61 Million

Rs6.34 Billion INR

Market Cap Rank

#20627 Global

#1148 in India

Share Price

Rs268.20

Change (1 day)

+2.01%

52-Week Range

Rs81.38 - Rs268.20

All Time High

Rs507.50